Ngā hua rapu - Dylan Conklin

  • E whakaatu ana i te 1 - 9 hua o te 9
Whakamahine hua
  1. 1
    PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

    PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro mā Richard S. Finn, Judy Dering, Dylan Conklin, Ondrej Kalous, David J. Cohen, Amrita J. Desai, Charles Ginther, Mohammad Atefi, Isan Chen, Camilla Fowst, Gerret Los, Dennis J. Slamon

    I whakaputaina 2009
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer

    Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer mā Zev A. Wainberg, Adrian Anghel, Amy M. Rogers, Amrita J. Desai, Ondrej Kalous, Dylan Conklin, Raul Ayala, Neil A. O’Brien, Cornelia Quadt, Mikhail Akimov, Dennis J. Slamon, Richard S. Finn

    I whakaputaina 2013
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib

    Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib mā Ondrej Kalous, Dylan Conklin, Amrita J. Desai, Neil A. O’Brien, Charles Ginther, Lee Anderson, David J. Cohen, Carolyn D. Britten, Ian W. Taylor, James G. Christensen, Dennis J. Slamon, Richard S. Finn

    I whakaputaina 2012
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT

    Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT mā Neil A. O’Brien, K McDonald, Tong Luo, Erika von Euw, Ondrej Kalous, Dylan Conklin, Sara A. Hurvitz, Emmanuelle di Tomaso, Christian Schnell, Ronald Linnartz, Richard S. Finn, Samit Hirawat, Dennis J. Slamon

    I whakaputaina 2014
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer

    Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer mā Neil A. O’Brien, Dylan Conklin, Richard P. Beckmann, Tong Luo, Kevin Chau, Josh D. Thomas, Ann Mc Nulty, Christophe C. Marchal, Ondrej Kalous, Erika von Euw, Sara A. Hurvitz, Colleen Mockbee, Dennis J. Slamon

    I whakaputaina 2018
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer

    Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer mā Neil A. O’Brien, Martina S.J. McDermott, Dylan Conklin, Tong Luo, Raul Ayala, Suruchi Salgar, Kevin Chau, Emmanuelle DiTomaso, Naveen Babbar, Faye Su, Alex Gaither, Sara A. Hurvitz, Ronald Linnartz, Kristine Rose, Samit Hirawat, Dennis J. Slamon

    I whakaputaina 2020
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines

    Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines mā Eniko Papp, Dorothy Hallberg, Gottfried E. Konecny, Daniel C. Bruhm, Vilmos Adleff, Michaël Noë, Ioannis Kagiampakis, Doreen N. Palsgrove, Dylan Conklin, Yasuto Kinose, James R. White, Michael F. Press, Ronny Drapkin, Hariharan Easwaran, Stephen B. Baylin, Dennis J. Slamon, Victor E. Velculescu, Robert B. Scharpf

    I whakaputaina 2018
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    Concise total syntheses of (–)-jorunnamycin A and (–)-jorumycin enabled by asymmetric catalysis

    Concise total syntheses of (–)-jorunnamycin A and (–)-jorumycin enabled by asymmetric catalysis mā Eric R. Welin, Aurapat Ngamnithiporn, Max Klatte, Guillaume Lapointe, Gerit Pototschnig, Martina S.J. McDermott, Dylan Conklin, Christopher D. Gilmore, Pamela M. Tadross, Christopher K. Haley, Kenji Negoro, Emil Glibstrup, Christian U. Grünanger, Kevin M. Allan, Scott C. Virgil, Dennis J. Slamon, Brian M. Stoltz

    I whakaputaina 2018
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays

    Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays mā Jun Li, Wei Zhao, Rehan Akbani, Wenbin Liu, Zhenlin Ju, Shiyun Ling, Christopher P. Vellano, Paul Roebuck, Qinghua Yu, Agda Karina Eterovic, Lauren A. Byers, Michael A. Davies, Wanleng Deng, Y.N. Vashisht Gopal, Guo Chen, Erika M. von Euw, Dennis J. Slamon, Dylan Conklin, John V. Heymach, Adi F. Gazdar, John D. Minna, Jeffrey N. Myers, Yiling Lu, Gordon B. Mills, Han Liang

    I whakaputaina 2017
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: